Can you say "no risk" in Indian pharma promotional material?

Restricted. Not as an absolute claim. Clause 2.2 of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 does not name the phrase 'no risk'. But it says it must not be stated categorically that a medicine has no side effects, toxic hazards, or risk of addiction. In our reading, an absolute 'no risk' claim would in effect include that statement, so Clause 2.2 would bar it. It would also mislead, which Clause 1.3 forbids.

In short

Status: restricted. In our reading, the absolute claim falls within Clause 2.2's bar and would mislead under Clause 1.3. Qualified safety statements are allowed.
Governing instrument: Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 2.2, read with the duty not to mislead in Clause 1.3
UCPMP 2024 does not name this term.
First checked by two independent AI models against the live web. Citations re-checked on 6 October 2026. They were checked against the official text of the Code.

Which instrument governs this

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 2.2, read with the duty not to mislead in Clause 1.3

UCPMP 2024 does not name this phrase. Clause 2.2 bars stating categorically that a medicine has no side effects, toxic hazards, or risk of addiction. No evidence makes that categorical statement acceptable. What can be said is a qualified safety statement tied to the evidence.

What verification returned

Not as an absolute claim. Clause 2.2 of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 does not name the phrase 'no risk'. But it says it must not be stated categorically that a medicine has no side effects, toxic hazards, or risk of addiction. In our reading, an absolute 'no risk' claim would in effect include that statement, so Clause 2.2 would bar it. It would also mislead, which Clause 1.3 forbids. Qualified, specific and substantiated safety statements, tied to the evidence and the product information, may be used.

How this was checked

Two independent AI models were asked the same question against the live web. They were Gemini 2.5 Pro with Google Search grounding, and OpenAI GPT-5 with web search. A third model then judged whether they agreed on the substance rather than the wording. Every source cited was fetched over HTTP to confirm it exists. A fetch confirms only that a source exists. It does not confirm that the source supports the statement. So on 6 October 2026 the citations on this page were re-checked. They were checked against the official text of the Code. They were corrected where they were wrong. Terms that did not reach agreement between the models are not published.

Sources checked

Frequently asked questions

Can you say "no risk" in pharma promotion in India?

Which code governs the use of 'no risk'?

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 2.2, read with the duty not to mislead in Clause 1.3

How reliable is this answer?

It was first checked on 10 September 2026 by two independent AI models, Gemini 2.5 Pro and GPT-5. Both worked against the live web, and their answers were adjudicated for agreement. Every cited source was fetched to confirm it exists. A fetch confirms only that a source exists. So on 6 October 2026 the citations were re-checked. They were checked against the official text of the Code. They were corrected where they were wrong. Terms that did not reach agreement are not published. The Code can change, so check against the source before relying on it.

Check it before MLR does

Collateral Advisor flags this term in the pages you upload, for your team to review in context.

Try Free: Upload a Page Talk to us

Free trial, no card needed. MarketingSense is a pre-MLR advisory assistant. Your medical, legal and regulatory team still makes the final call.